Form D · Biotechnology
OncoXome, Inc.
North Hollywood, CA · CIK 0001963883
Offering snapshot reported Feb 13, 2023 · SEC filing
- Reported sold
- $171K Offering amount: $1M
- Investors reported
- 2 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Dec 2, 2022 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Feb 13, 2023 | Initial | $170,500 | No comparison | 2 | SEC filing |
Offering details
- Securities
- Debt, Option to acquire, Security to be acquired
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-473287
Source: Form D, filed Feb 13, 2023. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Erick Gamelin | Director, Executive |
| Auriane Gamelin | Director, Executive |
| Laurence Gamelin | Director, Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
10824 Bloomfield Street #207
North Hollywood, CA, 91602
North Hollywood, CA, 91602